Search results for "From ACP Journal Club"


 
Results 11 - 20 of about 116 for "From ACP Journal Club".
Sort by: Relevance | Newest | Oldest

In obesity with T2DM, biliopancreatic diversion increased T2DM remission vs. medical and lifestyle therapy at 10 y

Previous research has shown short-term remission of type 2 diabetes after bariatric surgery, but a decade of data from this randomized trial should reassure patients of the favorable long-term benefits and safety of this intervention, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/06/11/9.htm
11 Jun 2021

In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs

A meta-analysis identified relative benefits of sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) based on individual cardiovascular and renal risks.
https://diabetes.acponline.org/archives/2021/06/11/8.htm
11 Jun 2021

KDIGO made 12 recommendations for managing diabetes with CKD

The kidney group's guideline supports metformin and sodium–glucose cotransporter-2 inhibitors as first-line therapies for patients with chronic kidney disease (CKD) based on consistent trial data showing their effectiveness, noted an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2021/03/12/6.htm
12 Mar 2021

In men who are overweight or obese, adding testosterone therapy reduced glucose intolerance/T2DM

A industry-funded trial found improved glucose control in men randomized to testosterone injections, but some of its claims were exaggerated, and routine use of testosterone therapy to prevent or reverse type 2 diabetes is not recommended, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/05/14/7.htm
14 May 2021

In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors

A cohort study's finding of increased risk of diabetic ketoacidosis with sodium-glucose cotransporter-2 (SGLT2) inhibitors is relevant to clinical decision making, but not definitive given the limitations of observational research, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2021/01/08/6.htm
8 Jan 2021

GLP-1 RA plus SGLT-2 inhibitor vs. either drug alone reduces HbA1c and SBP

The finding that combining glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT-2) inhibitors improves glycemic control and systolic blood pressure (SBP) without increasing hypoglycemia is important, but additional cost-effectiveness research on the drugs is needed, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/12/11/9.htm
11 Dec 2020

In T2DM, weekly insulin icodec did not differ from daily glargine for reducing HbA1c or significant/severe hypoglycemia

An ACP Journal Club commentary pointed out that use of once-weekly insulin for patients with type 2 diabetes will require more cautious dose-titration algorithms and less stringent glycemic targets to avoid hypoglycemia.
https://diabetes.acponline.org/archives/2021/03/12/7.htm
12 Mar 2021

Some glucose-lowering drugs reduce risk for major adverse cardiac events

An umbrella review found cardiovascular benefits from sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, but an ACP Journal Club commentary cautioned that included patients were on a wide array of background treatments.
https://diabetes.acponline.org/archives/2020/08/14/7.htm
14 Aug 2020

SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes

Diabetic ketoacidosis (DKA) is rare with sodium-glucose co-transporter-2 (SGLT2) inhibitors but more common than with control medications, and clinicians should be vigilant in identifying euglycemic DKA in patients on these drugs, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2020/11/13/6.htm
13 Nov 2020

SGLT2 inhibitors reduce all-cause mortality

A recent meta-analysis found lowered mortality risk with sodium-glucose cotransporter-2 (SGLT2) inhibitors, and an ACP Journal Club commentary added that other trials have shown beneficial effects of the drug class on kidney function in patients with type 2 diabetes.
https://diabetes.acponline.org/archives/2021/05/14/6.htm
14 May 2021

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next